The U.S. Food and Drug Administration has granted tentative approval to the first generic version of lenacapavir, a long-acting injectable medicine designed to prevent HIV infection.

Developed by India's Dr. Reddy’s Laboratories, the generic medicine offers a potentially more affordable alternative to Gilead Sciences’ branded treatment. Unlike daily HIV-prevention tablets, lenacapavir is administered twice a year, offering another option for people at risk of infection.

The generic version is intended for 120 low- and middle-income countries covered by Gilead’s voluntary licensing programme. Global health partners expect its price to be approximately $40 per person annually, with initial supplies anticipated by the end of 2026 and broader availability in 2027.

The FDA decision is a significant regulatory milestone, but it does not mean the generic can immediately be sold through U.S. pharmacies. Tentative approval allows eligible procurement and helps other countries rely on the FDA's assessment when considering regulatory clearance.

The development could improve access to long-acting HIV prevention, particularly in countries where the cost and practical challenges of daily medication have limited access to preventive treatment.